US Bancorp DE increased its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 69.9% during the second quarter, Holdings Channel reports. The institutional investor owned 6,014 shares of the medical instruments supplier’s stock after buying an additional 2,475 shares during the period. US Bancorp DE’s holdings in West Pharmaceutical Services were worth $569,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of WST. State Treasurer State of Michigan boosted its stake in shares of West Pharmaceutical Services by 1.7% in the second quarter. State Treasurer State of Michigan now owns 30,300 shares of the medical instruments supplier’s stock worth $2,864,000 after buying an additional 500 shares in the last quarter. Aperio Group LLC boosted its stake in shares of West Pharmaceutical Services by 47.8% in the second quarter. Aperio Group LLC now owns 45,228 shares of the medical instruments supplier’s stock worth $4,275,000 after buying an additional 14,632 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in shares of West Pharmaceutical Services by 3.8% in the second quarter. Louisiana State Employees Retirement System now owns 19,200 shares of the medical instruments supplier’s stock worth $1,815,000 after buying an additional 700 shares in the last quarter. LS Investment Advisors LLC boosted its stake in shares of West Pharmaceutical Services by 18.9% in the second quarter. LS Investment Advisors LLC now owns 6,185 shares of the medical instruments supplier’s stock worth $585,000 after buying an additional 983 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund boosted its stake in shares of West Pharmaceutical Services by 4.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 26,722 shares of the medical instruments supplier’s stock worth $2,526,000 after buying an additional 1,100 shares in the last quarter. 90.51% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services, Inc. (NYSE:WST) traded up 0.64% during trading on Wednesday, reaching $85.97. The company had a trading volume of 72,982 shares. The stock has a market capitalization of $6.36 billion, a P/E ratio of 36.90 and a beta of 1.10. West Pharmaceutical Services, Inc. has a 12-month low of $70.17 and a 12-month high of $99.91. The stock has a 50 day moving average of $91.30 and a 200-day moving average of $88.88.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.66 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. The business had revenue of $397.60 million during the quarter, compared to the consensus estimate of $406 million. During the same period in the previous year, the firm posted $0.59 earnings per share. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. On average, analysts forecast that West Pharmaceutical Services, Inc. will post $2.69 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Wednesday, October 18th will be paid a dividend of $0.14 per share. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.13. This represents a $0.56 annualized dividend and a dividend yield of 0.66%. The ex-dividend date is Tuesday, October 17th. West Pharmaceutical Services’s payout ratio is presently 22.22%.

WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/us-bancorp-de-has-569000-stake-in-west-pharmaceutical-services-inc-wst/1496163.html.

A number of analysts have recently commented on the company. BidaskClub cut West Pharmaceutical Services from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 3rd. Zacks Investment Research cut West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $90.00 price target on shares of West Pharmaceutical Services in a research report on Thursday, June 8th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $90.18.

In other news, CFO William J. Federici sold 54,996 shares of West Pharmaceutical Services stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $95.45, for a total transaction of $5,249,368.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.